Conference Day One | Wednesday, October 29

8:00 am Check- In & Morning Coffee

8:50 am Chair’s Opening Remarks

REVIEWING CNS TARGETING GENE THERAPY PROGRAMS IN THE CLINIC TO LEARN FROM SUCCESSES & FAILURES TO TURBOCHARGE DEVELOPMENT

9:00 am Navigating New Clinical Data to Hone the Current State of Play in the Industry & Implement Learnings onto Your Gene Therapy

  • Dunni Odumosu Vice President & Head of Global Regulatory Affairs & Sciences, Gene Therapy, BridgeBio Pharma, Inc.

Synopsis

  • Evaluating clinical data to take back the learnings from it
  • Translating clinical outcomes into your gene therapy development
  • Learning from clinical trials how to best address challenges related to safety and immunogenicity

9:30 am Identifying the Reasons Behind Failures in Clinical Trials to Learn from Them & Update Preclinical Testing & Clinical Trial Design

Synopsis

  • Analyzing recent clinical trial failures to determine the cause
  • Understanding how preclinical testing can be updated to prevent clinical failures
  • Turning failures into successes by learning from errors and strengthening clinical trial design

10:00 am Roundtable Discussion: Analyzing a Commercialized CNS Targeting Gene Therapy Program to Understand How to Successfully Take Your Product from Bench to Bedside

Synopsis

  • Deconstructing a full development life cycle to commercialization to understand the importance of each step
  • Examining the key challenges in each step from discovery to clinical development and manufacturing
  • Identifying key commercial insights and data to support your trials

10:30 am Morning Break & Speed Networking

Synopsis

This session is an opportunity to connect with peers and hold in-depth conversations with some of the brightest minds in the gene therapy industry to establish meaningful and lasting relationships

INNOVATING NOVEL VECTOR DEVELOPMENT & OPTIMIZING EXISTING VECTORS TO SUCCESSFULLY CROSS THE BLOOD-BRAIN BARRIER & IMPROVE CNS TARGETING

11:30 am Finding the Needle in the Haystack: Finding the Right Capsid to Successfully Deliver Your Gene Therapy to the Brain

  • Ralf Schmid Associate Director - Preclinical Research, Novartis AG

Synopsis

  • What are the approaches to achieve a suitable biodistribution in the primate brain
  • How can engineered capsids help to achieve suitable biodistribution in the primate brain? What is possible today, and what can we expect in the near future?
  • What are some of the opportunities and challenges for moving engineered capsids towards the clinic?

12:00 pm Reprogramming AAV Capsids to Target Human Receptors for Enhanced CNS Delivery

Synopsis

  • Optimizing for translation in the clinic should start with capsids interacting with human receptors
  • Regulatory guidance in gene therapy and direct FDA feedback across multiple programs outlines preclinical path for human-specific capsid and use of humanized animal models
  • Surrogate mouse BBB-crossing capsids can be used in efficacy studies in parallel with distribution studies enabling dose translation between surrogate and clinical capsids targeting human receptors

12:30 pm Improving Likelihood of Clinical Translation by Engineering Novel AAV Capsids that Bind BBB Receptors

  • John Reece-Hoyes Senior Director & Head of Vector Biology, Affinia Therapeutics

Synopsis

  • Identified capsids that bind both human and NHP orthologs of receptors expressed in the BBB
  • AI-powered approach to further optimize CNS tropism
  • Validation of CNS biodistribution in mouse, NHP, and human models

1:00 pm Lunch & Networking

IMPROVING THERAPEUTIC EFFICACY TO CNS DISEASES BY REDUCING OFF-TARGET TOXICITIES & PREVENTING IMMUNOGENICITY

2:00 pm Machine-Guided Design of AAV Capsids for Highly Specific CNS-IV Delivery

  • Eric Kelsic Chief Executive Officer & Co-Founder, Dyno Therapeutics

Synopsis

  • Multi-property optimization of capsid sequences using machine learning
  • Demonstrating efficient pan-brain CNS-IV gene delivery and exceptional liver detargeting in adult Cyno monkeys
  • Confirming conservation of BBB-crossing mechanisms between NHP and humans

2:30 pm Balancing Durability & Safety to Ensure Efficacy of Therapy Without Inducing Systemic Toxicity

Synopsis

  • Exploring the balance between durability and toxicity to correctly dose the patient
  • Identifying the correct balance to ensure high efficacy
  • Examining the drawback of high toxicity and low efficacy on clinical trial success

3:00 pm Afternoon Networking Break

4:00 pm Roundtable Discussion: Exploring the Effects of Toxicity on the Liver & Other Organs to Understand the True Effect of the Gene Therapy on the Entire Body

Synopsis

  • Discuss and learn how you can manage and benchmark toxicity
  • Expanding beyond the liver to understand the effects of toxicity on other vital organs
  • Reviewing how to control systemic toxicity and not just toxicity to the liver

5:00 pm Chair’s Closing Remarks

5:10 pm End of Conference Day One